Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Exenatide"" wg kryterium: Temat


Tytuł :
GLP-1 receptor agonists for Parkinson's disease.
Autorzy :
Mulvaney CA; Lancaster Medical School, Lancaster University, Lancaster, UK.
Duarte GS; Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina de Lisboa, Lisboa, Portugal.; Instituto de Medicina Molecular, Lisboa, Portugal.
Handley J; Lancaster Medical School, Lancaster University, Lancaster, UK.; Department of Neurology, Salford Royal Hospital, Salford, UK.
Evans DJ; Lancaster Medical School, Lancaster University, Lancaster, UK.
Menon S; Department of Medicine, McMaster University, Hamilton, Canada.
Wyse R; The Cure Parkinson's Trust, London, UK.
Emsley HC; Lancaster Medical School, Lancaster University, Lancaster, UK.; Department of Neurology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.
Pokaż więcej
Źródło :
The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2020 Jul 23; Vol. 7. Cochrane AN: CD012990. Date of Electronic Publication: 2020 Jul 23.
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms :
Exenatide/*therapeutic use
Glucagon-Like Peptide-1 Receptor/*agonists
Parkinson Disease/*drug therapy
Bias ; Double-Blind Method ; Exenatide/administration & dosage ; Exenatide/adverse effects ; Humans ; Hypoglycemic Agents/administration & dosage ; Hypoglycemic Agents/therapeutic use ; Placebos/administration & dosage ; Quality of Life ; Randomized Controlled Trials as Topic ; Self Administration ; Single-Blind Method
Czasopismo naukowe
Tytuł :
Exenatide ameliorates experimental non-alcoholic fatty liver in rats via suppression of toll-like receptor 4/NFκB signaling: Comparison to metformin.
Autorzy :
Saad ZA; Medical Administration, Suez Canal University, Ismailia, Egypt.
Khodeer DM; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt. Electronic address: .
Zaitone SA; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt; Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Tabuk, Tabuk, Saudi Arabia.
Ahmed AAM; Department of Histology, Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt.
Moustafa YM; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt.
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2020 Jul 15; Vol. 253, pp. 117725. Date of Electronic Publication: 2020 Apr 27.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Exenatide/*pharmacology
Hypoglycemic Agents/*pharmacology
Inflammation/*drug therapy
Non-alcoholic Fatty Liver Disease/*drug therapy
Animals ; Body Weight/drug effects ; Diet, High-Fat ; Disease Progression ; Dose-Response Relationship, Drug ; Exenatide/administration & dosage ; Hypoglycemic Agents/administration & dosage ; Inflammation/pathology ; Insulin Resistance ; Male ; Metformin/pharmacology ; NF-kappa B/metabolism ; Non-alcoholic Fatty Liver Disease/pathology ; Rats ; Rats, Wistar ; Signal Transduction/drug effects ; Toll-Like Receptor 4/metabolism
Czasopismo naukowe
Tytuł :
Targeted Optical Imaging of the Glucagonlike Peptide 1 Receptor Using Exendin-4-IRDye 800CW.
Autorzy :
Boss M; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands .
Bos D; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Frielink C; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Sandker G; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Ekim S; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Marciniak C; Department of General and Endocrine Surgery, University Hospital 2 Lille, Lille, France.
Pattou F; Department of General and Endocrine Surgery, University Hospital 2 Lille, Lille, France.
van Dam G; Department of Surgery, University Medical Center Groningen, Groningen, The Netherlands; and.
van Lith S; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Brom M; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Gotthardt M; Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
Buitinga M; Department of Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium.
Pokaż więcej
Źródło :
Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2020 Jul; Vol. 61 (7), pp. 1066-1071. Date of Electronic Publication: 2020 Jan 10.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Benzenesulfonates/*chemistry
Exenatide/*chemistry
Glucagon-Like Peptide-1 Receptor/*metabolism
Indoles/*chemistry
Optical Imaging/*methods
Animals ; Biological Transport ; CHO Cells ; Cricetulus ; Exenatide/metabolism ; Exenatide/pharmacokinetics ; Female ; Mice ; Mice, Nude ; Pancreas/metabolism ; Swine ; Tissue Distribution
Czasopismo naukowe
Tytuł :
LncRNA-Malat1 is Involved in Lipotoxicity-Induced ß-cell Dysfunction and the Therapeutic Effect of Exendin-4 via Ptbp1.
Autorzy :
Xiong L; Department of Endocrinology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Gong Y; Department of Endocrinology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.; Department of Geriatrics, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Wu L; Department of Endocrinology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Li J; Department of Endocrinology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.; Department of Geriatrics, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
He W; Department of Endocrinology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Zhu X; Department of Pharmacology, Zhong‑Shan School of Medicine, Sun Yat‑sen University, Guangzhou, Guangdong, China.
Xiao H; Department of Endocrinology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
Pokaż więcej
Źródło :
Endocrinology [Endocrinology] 2020 Jul 01; Vol. 161 (7).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Diabetes Mellitus, Experimental/*metabolism
Exenatide/*therapeutic use
Heterogeneous-Nuclear Ribonucleoproteins/*metabolism
Islets of Langerhans/*metabolism
Polypyrimidine Tract-Binding Protein/*metabolism
RNA, Long Noncoding/*metabolism
Animals ; Diabetes Mellitus, Experimental/drug therapy ; Diabetes Mellitus, Experimental/etiology ; Drug Evaluation, Preclinical ; Exenatide/pharmacology ; Islets of Langerhans/drug effects ; Male ; Mice ; Pyruvate Kinase/metabolism
Czasopismo naukowe
Tytuł :
The GLP-1 analog exendin-4 modulates HSP72 expression and ERK1/2 activity in BTC6 mouse pancreatic cells.
Autorzy :
Madhu D; Biochemistry and Molecular Biology Department, Dasman Diabetes Institute, Kuwait.
Khadir A; Genetics and Bioinformatics Department, Dasman Diabetes Institute, Kuwait.
Hammad M; Biochemistry and Molecular Biology Department, Dasman Diabetes Institute, Kuwait.
Kavalakatt S; Biochemistry and Molecular Biology Department, Dasman Diabetes Institute, Kuwait.
Dehbi M; Diabetes Research Centre, QBRI, Hamad Bin Khalifa University, Doha, Qatar.
Al-Mulla F; Genetics and Bioinformatics Department, Dasman Diabetes Institute, Kuwait.
Abubaker J; Biochemistry and Molecular Biology Department, Dasman Diabetes Institute, Kuwait.
Tiss A; Biochemistry and Molecular Biology Department, Dasman Diabetes Institute, Kuwait. Electronic address: .
Pokaż więcej
Źródło :
Biochimica et biophysica acta. Proteins and proteomics [Biochim Biophys Acta Proteins Proteom] 2020 Jul; Vol. 1868 (7), pp. 140426. Date of Electronic Publication: 2020 Apr 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Exenatide/*metabolism
Glucagon-Like Peptide 1/*analogs & derivatives
HSP72 Heat-Shock Proteins/*metabolism
Insulin-Secreting Cells/*metabolism
MAP Kinase Signaling System/*physiology
Animals ; Apoptosis/drug effects ; Cell Line ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Diabetes Mellitus, Type 2/metabolism ; Endoplasmic Reticulum/drug effects ; Endoplasmic Reticulum/metabolism ; Exenatide/pharmacology ; HSP40 Heat-Shock Proteins ; Membrane Glycoproteins ; Mice ; Molecular Chaperones ; Phosphorylation ; Protective Agents/pharmacology ; Protein Interaction Maps ; Up-Regulation
Czasopismo naukowe
Tytuł :
[Effects of Exenatide-4 on proliferation, migration and osteogenic differentiation of human periodontal ligament stem cells].
Autorzy :
Liang QY; National Shandong Provincial Key Laboratory of Oral Tissue Regeneration,Department of Periodontology, School of Stomatology, Shandong University. Jinan 250012, China. E-mail:.
DU LQ
Zhang R
Ding T
Ge SH
Pokaż więcej
Źródło :
Shanghai kou qiang yi xue = Shanghai journal of stomatology [Shanghai Kou Qiang Yi Xue] 2020 Jun; Vol. 29 (3), pp. 225-230.
Typ publikacji :
Journal Article
MeSH Terms :
Exenatide*/pharmacology
Periodontal Ligament*
Cell Differentiation ; Cell Proliferation ; Cells, Cultured ; Humans ; Osteogenesis ; Stem Cells
Czasopismo naukowe
Tytuł :
Twelve weeks of exenatide treatment increases [ F]fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males.
Autorzy :
Janssen LGM; Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands.
Nahon KJ; Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands.
Bracké KFM; Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands.
van den Broek D; Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands.
Smit R; Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands.
Sardjoe Mishre ASD; Department of Radiology, C.J. Gorter Center for High Field MRI, Leiden University Medical Center, Leiden, the Netherlands.
Koorneef LL; Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands.
Martinez-Tellez B; Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands; PROFITH (PROmoting FITness and Health Through Physical Activity) Research Group, Department of Physical Education and Sports, Faculty of Sport Sciences, University of Granada, Granada, Spain.
Burakiewicz J; Department of Radiology, C.J. Gorter Center for High Field MRI, Leiden University Medical Center, Leiden, the Netherlands.
Kan HE; Department of Radiology, C.J. Gorter Center for High Field MRI, Leiden University Medical Center, Leiden, the Netherlands.
van Velden FHP; Department of Radiology, Division of Nuclear Medicine, Leiden University Medical Center, Leiden, the Netherlands.
Pereira Arias-Bouda LM; Department of Radiology, Division of Nuclear Medicine, Leiden University Medical Center, Leiden, the Netherlands; Department of Nuclear Medicine, Alrijne Hospital, Leiderdorp, the Netherlands.
de Geus-Oei LF; Department of Radiology, Division of Nuclear Medicine, Leiden University Medical Center, Leiden, the Netherlands; Biomedical Photonic Imaging Group, University of Twente, Enschede, the Netherlands.
Berbée JFP; Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands.
Jazet IM; Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands.
Boon MR; Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: .
Rensen PCN; Department of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, the Netherlands.
Pokaż więcej
Źródło :
Metabolism: clinical and experimental [Metabolism] 2020 May; Vol. 106, pp. 154167. Date of Electronic Publication: 2020 Jan 23.
Typ publikacji :
Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Adipose Tissue, Brown/*drug effects
Adipose Tissue, Brown/*metabolism
Energy Metabolism/*drug effects
Exenatide/*pharmacology
Fluorodeoxyglucose F18/*pharmacokinetics
Adipose Tissue, Brown/diagnostic imaging ; Adult ; Body Composition/drug effects ; Body Weight/drug effects ; Exenatide/therapeutic use ; Humans ; Male ; Oxidation-Reduction/drug effects ; Oxidative Phosphorylation/drug effects ; Positron Emission Tomography Computed Tomography ; Rest/physiology ; Young Adult
Czasopismo naukowe
Tytuł :
Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies.
Autorzy :
Morieri ML; Department of Medicine, University of Padova, 35128 Padova, Italy; Division of Metabolic Diseases, Padova Hospital, 35128 Padova, Italy.
Rigato M; ULSS2 Diabetology Service, 31100 Treviso, Italy.
Frison V; Internal Medicine and Diabetology Service, ULSS6, 35013 Cittadella, Italy.
Simioni N; Internal Medicine and Diabetology Service, ULSS6, 35013 Cittadella, Italy.
D'Ambrosio M; Diabetology Service ULSS6, 35043 Monselice, Italy.
Tadiotto F; Diabetology Service ULSS6, 35043 Monselice, Italy.
Paccagnella A; ULSS2 Diabetology Service, 31100 Treviso, Italy.
Lapolla A; Department of Medicine, University of Padova, 35128 Padova, Italy; Diabetology Service ULSS6, 35100 Padova, Italy.
Avogaro A; Department of Medicine, University of Padova, 35128 Padova, Italy; Division of Metabolic Diseases, Padova Hospital, 35128 Padova, Italy.
Fadini GP; Department of Medicine, University of Padova, 35128 Padova, Italy; Division of Metabolic Diseases, Padova Hospital, 35128 Padova, Italy. Electronic address: .
Pokaż więcej
Źródło :
Metabolism: clinical and experimental [Metabolism] 2020 May; Vol. 106, pp. 154190. Date of Electronic Publication: 2020 Feb 25.
Typ publikacji :
Journal Article; Meta-Analysis; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Diabetes Mellitus, Type 2/*drug therapy
Exenatide/*administration & dosage
Glucagon-Like Peptides/*analogs & derivatives
Immunoglobulin Fc Fragments/*administration & dosage
Liraglutide/*administration & dosage
Observational Studies as Topic/*statistics & numerical data
Recombinant Fusion Proteins/*administration & dosage
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/epidemiology ; Drug Administration Schedule ; Drug Therapy, Combination ; Exenatide/adverse effects ; Female ; Follow-Up Studies ; Glucagon-Like Peptides/administration & dosage ; Glucagon-Like Peptides/adverse effects ; Humans ; Immunoglobulin Fc Fragments/adverse effects ; Liraglutide/adverse effects ; Male ; Middle Aged ; Recombinant Fusion Proteins/adverse effects ; Retrospective Studies ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Oral delivery of exenatide-loaded hybrid zein nanoparticles for stable blood glucose control and β-cell repair of type 2 diabetes mice.
Autorzy :
Bao X; State Key Laboratory of Molecular Engineering of Polymers, Collaborative Innovation Center of Polymers and Polymer Composite Materials, Department of Macromolecular Science, Fudan University, Shanghai, 200438, China.
Qian K; Key Laboratory of Smart Drug Delivery, Ministry of Education, School of Pharmacy, Fudan University, Shanghai, 201203, China.
Yao P; State Key Laboratory of Molecular Engineering of Polymers, Collaborative Innovation Center of Polymers and Polymer Composite Materials, Department of Macromolecular Science, Fudan University, Shanghai, 200438, China. .
Pokaż więcej
Źródło :
Journal of nanobiotechnology [J Nanobiotechnology] 2020 Apr 28; Vol. 18 (1), pp. 67. Date of Electronic Publication: 2020 Apr 28.
Typ publikacji :
Journal Article
MeSH Terms :
Exenatide/*pharmacology
Hypoglycemic Agents/*pharmacology
Insulin-Secreting Cells/*drug effects
Nanoparticles/*chemistry
Zein/*chemistry
Administration, Oral ; Animals ; Blood Glucose/analysis ; Cholic Acid/chemistry ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/pathology ; Drug Carriers/chemistry ; Drug Carriers/pharmacokinetics ; Exenatide/administration & dosage ; Exenatide/chemistry ; Gastrointestinal Tract/chemistry ; Gastrointestinal Tract/pathology ; Glycated Hemoglobin A/analysis ; Half-Life ; Hypoglycemic Agents/administration & dosage ; Hypoglycemic Agents/chemistry ; Insulin-Secreting Cells/classification ; Insulin-Secreting Cells/metabolism ; Intestinal Mucosa/metabolism ; Male ; Mice ; Mice, Inbred ICR ; Nanoparticles/metabolism ; Permeability/drug effects ; Phosphatidylcholines/chemistry
Czasopismo naukowe
Tytuł :
Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial.
Autorzy :
Zhang J; Department of Endocrinology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Graduate School of Peking Union Medical College, No. 1 Dahua Road, Dong Dan, Beijing, 100730, P. R. China.
Xian TZ; Department of Endocrinology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 Dahua Road, Dong Dan, Beijing, 100730, P. R. China.
Wu MX; Department of Ultrasound, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 Dahua Road, Dong Dan, Beijing, 100730, P. R. China.
Li C; Department of Ultrasound, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 Dahua Road, Dong Dan, Beijing, 100730, P. R. China.
Pan Q; Department of Endocrinology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 Dahua Road, Dong Dan, Beijing, 100730, P. R. China. .
Guo LX; Department of Endocrinology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Graduate School of Peking Union Medical College, No. 1 Dahua Road, Dong Dan, Beijing, 100730, P. R. China. .
Pokaż więcej
Źródło :
Cardiovascular diabetology [Cardiovasc Diabetol] 2020 Apr 25; Vol. 19 (1), pp. 48. Date of Electronic Publication: 2020 Apr 25.
Typ publikacji :
Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Carotid Intima-Media Thickness*
Carotid Arteries/*drug effects
Carotid Artery Diseases/*drug therapy
Diabetes Mellitus, Type 2/*drug therapy
Exenatide/*administration & dosage
Hypoglycemic Agents/*administration & dosage
Incretins/*administration & dosage
Insulin Aspart/*administration & dosage
Adult ; Aged ; Beijing ; Blood Glucose/drug effects ; Blood Glucose/metabolism ; Carotid Arteries/diagnostic imaging ; Carotid Artery Diseases/diagnostic imaging ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/diagnosis ; Disease Progression ; Drug Administration Schedule ; Exenatide/adverse effects ; Female ; Humans ; Hypoglycemic Agents/adverse effects ; Incretins/adverse effects ; Insulin Aspart/adverse effects ; Male ; Middle Aged ; Predictive Value of Tests ; Time Factors ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
A once-monthly GLP-1 receptor agonist for treatment of diabetic cats.
Autorzy :
Schneider EL; ProLynx, San Francisco, CA, USA.
Reid R; ProLynx, San Francisco, CA, USA.
Parkes DG; DGP Scientific Inc, Del Mar, CA, USA.
Lutz TA; University of Zurich, Institute of Veterinary Physiology, Zurich, Switzerland.
Ashley GW; ProLynx, San Francisco, CA, USA.
Santi DV; ProLynx, San Francisco, CA, USA. Electronic address: .
Pokaż więcej
Źródło :
Domestic animal endocrinology [Domest Anim Endocrinol] 2020 Jan; Vol. 70, pp. 106373. Date of Electronic Publication: 2019 Jul 08.
Typ publikacji :
Journal Article
MeSH Terms :
Cat Diseases/*drug therapy
Diabetes Mellitus/*veterinary
Exenatide/*analogs & derivatives
Exenatide/*pharmacokinetics
Glucagon-Like Peptide-1 Receptor/*agonists
Animals ; Area Under Curve ; Cats ; Diabetes Mellitus/drug therapy ; Exenatide/administration & dosage ; Exenatide/pharmacology ; Glucose Tolerance Test ; Half-Life ; Male
Czasopismo naukowe
Tytuł :
Intratracheal GLP-1 receptor agonist treatment up-regulates mucin via p38 and exacerbates emphysematous phenotype in mucus hypersecretory obstructive lung diseases.
Autorzy :
Nohara H; Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto, 862-0973, Japan; Program for Leading Graduate Schools 'HIGO (Health Life Science: Interdisciplinary and Glocal Oriented) Program', Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto, 862-0973, Japan.
Nakashima R; Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto, 862-0973, Japan.
Kamei S; Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto, 862-0973, Japan; Program for Leading Graduate Schools 'HIGO (Health Life Science: Interdisciplinary and Glocal Oriented) Program', Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto, 862-0973, Japan; Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, 714 Petit Science Center, 100 Piedmont Ave SE, Atlanta, GA30303, USA.
Fujikawa H; Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto, 862-0973, Japan; Program for Leading Graduate Schools 'HIGO (Health Life Science: Interdisciplinary and Glocal Oriented) Program', Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto, 862-0973, Japan.
Ueno-Shuto K; Laboratory of Pharmacology, Division of Life Science, Faculty of Pharmaceutical Sciences, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto, 860-0082, Japan.
Kawakami T; Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto, 862-0973, Japan.
Eto Y; Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto, 862-0973, Japan.
Suico MA; Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto, 862-0973, Japan; Global Center for Natural Resources Sciences, Faculty of Life Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto, 862-0973, Japan.
Li JD; Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, 714 Petit Science Center, 100 Piedmont Ave SE, Atlanta, GA30303, USA.
Kai H; Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto, 862-0973, Japan; Global Center for Natural Resources Sciences, Faculty of Life Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto, 862-0973, Japan.
Shuto T; Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto, 862-0973, Japan; Global Center for Natural Resources Sciences, Faculty of Life Sciences, Kumamoto University, 5-1 Oe-Honmachi, Chuo-ku, Kumamoto, 862-0973, Japan. Electronic address: .
Pokaż więcej
Źródło :
Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2020 Apr 02; Vol. 524 (2), pp. 332-339. Date of Electronic Publication: 2020 Jan 26.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Exenatide/*therapeutic use
Glucagon-Like Peptide-1 Receptor/*agonists
Hypoglycemic Agents/*therapeutic use
Lung Diseases, Obstructive/*drug therapy
Mucins/*genetics
p38 Mitogen-Activated Protein Kinases/*metabolism
Animals ; Cell Line ; Enzyme Activation/drug effects ; Exenatide/adverse effects ; Glucagon-Like Peptide-1 Receptor/metabolism ; Hypoglycemic Agents/adverse effects ; Lung Diseases, Obstructive/genetics ; Lung Diseases, Obstructive/metabolism ; Lung Diseases, Obstructive/pathology ; Mice, Inbred C57BL ; Mucins/metabolism ; Up-Regulation/drug effects
Czasopismo naukowe
Tytuł :
Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation.
Autorzy :
Wenjing H; Institute of Urology, the First Affiliated Hospital of Nanchang University, Nanchang, China.
Shao Y; Department of Oncology, the First Affiliated Hospital of Nanchang University, Nanchang, China.
Yu Y; Department of Oncology, the First Affiliated Hospital of Nanchang University, Nanchang, China.
Huang W; Department of Oncology, the First Affiliated Hospital of Nanchang University, Nanchang, China.
Feng G; Department of Oncology, the First Affiliated Hospital of Nanchang University, Nanchang, China.
Li J; Department of Oncology, the First Affiliated Hospital of Nanchang University, Nanchang, China.
Pokaż więcej
Źródło :
The Prostate [Prostate] 2020 Apr; Vol. 80 (5), pp. 367-375. Date of Electronic Publication: 2020 Jan 22.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Exenatide/*pharmacology
Phenylthiohydantoin/*analogs & derivatives
Prostatic Neoplasms/*drug therapy
Proto-Oncogene Proteins c-akt/*metabolism
Animals ; Cell Growth Processes/drug effects ; Cell Line, Tumor ; Cell Movement/drug effects ; Cell Nucleus/metabolism ; Drug Synergism ; Enzyme Activation/drug effects ; Exenatide/administration & dosage ; Glucagon-Like Peptide-1 Receptor/biosynthesis ; Humans ; Male ; Mice, Inbred BALB C ; Mice, Nude ; Neoplasm Invasiveness ; Phenylthiohydantoin/administration & dosage ; Phenylthiohydantoin/pharmacology ; Prostatic Neoplasms/enzymology ; Prostatic Neoplasms/pathology ; Random Allocation ; Receptors, Androgen/metabolism ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
GLP-1 receptor agonists in type 1 diabetes: a MAG1C bullet?
Autorzy :
Nauck MA; Diabetes Division, Katholisches Klinikum Bochum, St Josef Hospital, Ruhr-University Bochum, D-44791 Bochum, Germany. Electronic address: .
Meier JJ; Diabetes Division, Katholisches Klinikum Bochum, St Josef Hospital, Ruhr-University Bochum, D-44791 Bochum, Germany.
Pokaż więcej
Źródło :
The lancet. Diabetes & endocrinology [Lancet Diabetes Endocrinol] 2020 Apr; Vol. 8 (4), pp. 262-264. Date of Electronic Publication: 2020 Mar 02.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Diabetes Mellitus, Type 1*
Exenatide*
Blood Glucose ; Double-Blind Method ; Glucagon-Like Peptide-1 Receptor ; Humans ; Hypoglycemic Agents
Czasopismo naukowe
Tytuł :
Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.
Autorzy :
Standl E; Munich Diabetes Research Group e.V. at Helmholtz Centre, Neuherberg, Germany .
Stevens SR; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Lokhnygina Y; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Bethel MA; Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, U.K.
Buse JB; University of North Carolina School of Medicine, Chapel Hill, NC.
Gustavson SM; AstraZeneca Research and Development, Gaithersburg, MD.
Maggioni AP; ANMCO Research Center, Florence, Italy.
Mentz RJ; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Hernandez AF; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Holman RR
Pokaż więcej
Corporate Authors :
EXSCEL Study Group
Źródło :
Diabetes care [Diabetes Care] 2020 Mar; Vol. 43 (3), pp. 643-652. Date of Electronic Publication: 2019 Dec 27.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Cardiovascular Diseases/*epidemiology
Diabetes Mellitus, Type 2/*drug therapy
Diabetes Mellitus, Type 2/*epidemiology
Diabetic Angiopathies/*epidemiology
Exenatide/*therapeutic use
Hypoglycemia/*chemically induced
Hypoglycemia/*epidemiology
Acute Coronary Syndrome/epidemiology ; Acute Coronary Syndrome/etiology ; Aged ; Cardiovascular Diseases/blood ; Cardiovascular Diseases/etiology ; Comorbidity ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/complications ; Diabetic Angiopathies/blood ; Diabetic Angiopathies/etiology ; Double-Blind Method ; Exenatide/adverse effects ; Female ; Hospitalization/statistics & numerical data ; Humans ; Hypoglycemia/blood ; Hypoglycemia/pathology ; Hypoglycemic Agents/adverse effects ; Hypoglycemic Agents/therapeutic use ; Male ; Middle Aged ; Myocardial Infarction/blood ; Myocardial Infarction/epidemiology ; Myocardial Infarction/etiology ; Risk Factors ; Severity of Illness Index ; Stroke/blood ; Stroke/epidemiology ; Stroke/etiology
Czasopismo naukowe
Tytuł :
Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Autorzy :
Reed SD; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC .
Li Y; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Dakin HA; Oxford Health Economic Research Centre, University of Oxford, Oxford, U.K.
Becker F; Oxford Health Economic Research Centre, University of Oxford, Oxford, U.K.
Leal J; Oxford Health Economic Research Centre, University of Oxford, Oxford, U.K.
Gustavson SM; AstraZeneca Research and Development, Gaithersburg, MD.
Kartman B; AstraZeneca, Mölndal, Sweden.
Wittbrodt E; AstraZeneca Research and Development, Gaithersburg, MD.
Mentz RJ; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Pagidipati NJ; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
Bethel MA; Diabetes Trials Unit, University of Oxford, Oxford, U.K.
Gray AM; Oxford Health Economic Research Centre, University of Oxford, Oxford, U.K.
Holman RR; Diabetes Trials Unit, University of Oxford, Oxford, U.K.
Hernandez AF
Pokaż więcej
Corporate Authors :
EXSCEL Study Group
Źródło :
Diabetes care [Diabetes Care] 2020 Feb; Vol. 43 (2), pp. 374-381. Date of Electronic Publication: 2019 Dec 05.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Health Care Costs*/statistics & numerical data
Health Resources*/economics
Health Resources*/statistics & numerical data
Quality of Life*
Cardiovascular Diseases/*prevention & control
Diabetes Mellitus, Type 2/*drug therapy
Exenatide/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Cardiovascular Diseases/complications ; Cardiovascular Diseases/economics ; Cardiovascular Diseases/epidemiology ; Cause of Death ; Diabetes Mellitus, Type 2/economics ; Diabetes Mellitus, Type 2/epidemiology ; Diabetic Angiopathies/economics ; Diabetic Angiopathies/epidemiology ; Diabetic Angiopathies/prevention & control ; Exenatide/economics ; Female ; Follow-Up Studies ; Hospitalization/economics ; Hospitalization/statistics & numerical data ; Humans ; Hypoglycemic Agents/economics ; Hypoglycemic Agents/therapeutic use ; Incidence ; Intention to Treat Analysis ; Male ; Medicare/economics ; Medicare/statistics & numerical data ; Middle Aged ; United Kingdom/epidemiology ; United States/epidemiology
Czasopismo naukowe
Tytuł :
Therapeutic efficacy of arginine-rich exenatide on diabetic neuropathy in rats.
Autorzy :
Shekunova EV; RMC 'HOME OF PHARMACY', The Leningrad Region, Vsevolozhskiy District, 188663, Russia.
Kashkin VA; Valdman Institute of Pharmacology, First Pavlov State Medical University, St.-Petersburg, 197022, Russia; Sechenov Institute of Evolutionary Physiology and Biochemistry, St. Petersburg, 194223, Russia. Electronic address: .
Muzhikyan AА; Smorodintsev Research Institute of Influenza, St. Petersburg, 197376, Russia; Konstantinov Institute of Nuclear Physics, The Leningrad Region, Gatchina, 188300, Russia.
Makarova MN; RMC 'HOME OF PHARMACY', The Leningrad Region, Vsevolozhskiy District, 188663, Russia.
Balabanyan VY; Faculty of Fundamental Medicine of Lomonosov Moscow State University, Moscow, 119192, Russia.
Makarov VG; RMC 'HOME OF PHARMACY', The Leningrad Region, Vsevolozhskiy District, 188663, Russia.
Pokaż więcej
Źródło :
European journal of pharmacology [Eur J Pharmacol] 2020 Jan 05; Vol. 866, pp. 172835. Date of Electronic Publication: 2019 Nov 30.
Typ publikacji :
Journal Article
MeSH Terms :
Arginine/*chemistry
Diabetic Neuropathies/*drug therapy
Exenatide/*chemistry
Exenatide/*pharmacology
Animals ; Blood Glucose/metabolism ; Diabetic Neuropathies/blood ; Diabetic Neuropathies/pathology ; Diabetic Neuropathies/physiopathology ; Dose-Response Relationship, Drug ; Exenatide/therapeutic use ; Gene Expression Regulation/drug effects ; Glycated Hemoglobin A/metabolism ; Hyperalgesia/complications ; Insulin/metabolism ; Islets of Langerhans/drug effects ; Islets of Langerhans/pathology ; Locomotion/drug effects ; Male ; Organ Size/drug effects ; Rats ; Rats, Wistar ; Sciatic Nerve/drug effects ; Sciatic Nerve/pathology
Czasopismo naukowe
Tytuł :
Mono-PEGylates of exenatide in branched and dimeric structures can improve in vivo stability and hypoglycemic bioactivity.
Autorzy :
Thi Nguyen NT; Dept. of Bionanotechnology, Graduate School, South Korea.
Jung S; Dept. of Bionanotechnology, Graduate School, South Korea.
Lee SH; Dept. of Bionanotechnology, Graduate School, South Korea. Electronic address: .
Bae ON; Dept. of Bionanotechnology, Graduate School, South Korea.
Lee EK; College of Pharmacy, Hanyang University - ERICA, Ansan, 15588, South Korea. Electronic address: .
Pokaż więcej
Źródło :
Journal of biotechnology [J Biotechnol] 2019 Dec 20; Vol. 306, pp. 89-96. Date of Electronic Publication: 2019 Sep 30.
Typ publikacji :
Journal Article
MeSH Terms :
Exenatide/*chemistry
Exenatide/*pharmacology
Hypoglycemic Agents/*chemistry
Hypoglycemic Agents/*pharmacology
Polyethylene Glycols/*chemistry
Amino Acid Sequence ; Animals ; Blood Glucose/drug effects ; CHO Cells ; Cricetulus ; Cyclic AMP/metabolism ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/drug therapy ; Disease Models, Animal ; Exenatide/genetics ; Exenatide/therapeutic use ; Glucagon-Like Peptide-1 Receptor/agonists ; Glucagon-Like Peptide-1 Receptor/metabolism ; Half-Life ; Hypoglycemic Agents/therapeutic use ; Maleimides/chemistry ; Mice ; Mice, Nude ; Mice, Obese ; Molecular Weight
Czasopismo naukowe
Tytuł :
Preparation and evaluation of lactic acid acylated exenatide and its long-acting preparation.
Autorzy :
Wang A; School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University , Yantai , Shandong Province , People's Republic of China.
Yan X; School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University , Yantai , Shandong Province , People's Republic of China.
Liang R; School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University , Yantai , Shandong Province , People's Republic of China.
Wang L; State Key Laboratory of Long-Acting and Targeting Drug Delivery System, Shandong Luye Pharmaceutical Co., Ltd , Yantai , Shandong Province , People's Republic of China.
Chu L; School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University , Yantai , Shandong Province , People's Republic of China.
Sun K; School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University , Yantai , Shandong Province , People's Republic of China.
Fu F; School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University , Yantai , Shandong Province , People's Republic of China.
Pokaż więcej
Źródło :
Pharmaceutical development and technology [Pharm Dev Technol] 2019 Dec; Vol. 24 (10), pp. 1229-1235. Date of Electronic Publication: 2019 Aug 20.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Compounding/*methods
Exenatide/*chemistry
Hypoglycemic Agents/*chemistry
Lactic Acid/*chemistry
Acylation ; Animals ; Blood Glucose/analysis ; Delayed-Action Preparations ; Diabetes Mellitus, Experimental/blood ; Diabetes Mellitus, Experimental/drug therapy ; Drug Liberation ; Exenatide/blood ; Exenatide/therapeutic use ; Glucagon-Like Peptide-1 Receptor/agonists ; Hypoglycemic Agents/blood ; Hypoglycemic Agents/therapeutic use ; Male ; Mice, Inbred Strains ; Microspheres ; Rats, Sprague-Dawley
Czasopismo naukowe
Tytuł :
Preparation of [ Lu]Lu-DOTA-Ahx-Lys40-Exendin-4 for radiotherapy of insulinoma: a detailed insight into the radiochemical intricacies.
Autorzy :
Guleria M; Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India; Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India.
Das T; Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India; Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India. Electronic address: .
Amirdhanayagam J; Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India.
Sarma HD; Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India.
Dash A; Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India; Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India.
Pokaż więcej
Źródło :
Nuclear medicine and biology [Nucl Med Biol] 2019 Nov - Dec; Vol. 78-79, pp. 31-40. Date of Electronic Publication: 2019 Nov 09.
Typ publikacji :
Journal Article
MeSH Terms :
Exenatide/*chemistry
Exenatide/*therapeutic use
Heterocyclic Compounds, 1-Ring/*chemistry
Insulinoma/*radiotherapy
Lutetium/*therapeutic use
Radioisotopes/*therapeutic use
Animals ; Exenatide/pharmacokinetics ; Exenatide/urine ; Kidney/metabolism ; Mice ; Radiochemistry ; Tissue Distribution
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies